Enzo Biochem Valuation

Q: What is the Fair Price of ENZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ENZ ($0.97) is trading below our estimate of [[fair value]] ($12.14)

Is ENZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ENZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ENZ ($0.97) is trading below our estimate of fair value ($12.14)

Significantly Below Fair Value: ENZ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENZ?

Key metric: As ENZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ENZ. This is calculated by dividing ENZ's market cap by their current revenue.
What is ENZ's PS Ratio?
PS Ratio	1.6x
Sales	US$31.91m
Market Cap	US$51.57m

ENZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.08x
Enterprise Value/EBITDA	-0.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ENZ's PS Ratio compare to its peers?

The above table shows the PS ratio for ENZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.5x
PRE Prenetics Global	2.4x	93.6%	US$57.7m
ME 23andMe Holding	0.4x	n/a	US$81.4m
CCEL Cryo-Cell International	2.1x	1.0%	US$63.4m
CDIX Cardiff Lexington	13.1x	n/a	US$98.9m
ENZ Enzo Biochem	1.6x	n/a	US$51.6m

Price-To-Sales vs Peers: ENZ is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (4.5x).

Price to Sales Ratio vs Industry

How does ENZ's PS Ratio compare vs other companies in the US Healthcare Industry?

31 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$78.85b
CVS CVS Health	0.2x	4.6%	US$71.52b
COR Cencora	0.2x	6.4%	US$47.67b
CNC Centene	0.2x	5.5%	US$29.84b

31 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ENZ is expensive based on its Price-To-Sales Ratio (1.6x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is ENZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ENZ's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.0b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$87.32

8.0%

27.8%

Centene

US$29.8b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.35

2.8%

-18.7%

electroCore

US$64.1m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$9.92

-27.1%

80.4%